Drug Status Review

Is Retatrutide FDA Approved?

Retatrutide is an investigational weight management and metabolic therapy currently under clinical development. It is not FDA approved for commercial prescription use at this time.

Search Drug Index View Not Approved Drugs

Current FDA Status

Not FDA Approved

Retatrutide remains investigational and should only be viewed through clinical research and legitimate regulatory channels.

Overview

What is Retatrutide?

Retatrutide is a next-generation investigational therapy studied for obesity, weight loss, and metabolic disease management. It has attracted significant attention due to strong research interest and future approval potential.

Unlike approved medications such as Wegovy, Zepbound, Ozempic, and Mounjaro, Retatrutide has not completed FDA review and remains under active study.

Approval Status

Not FDA approved and still in clinical development.

Drug Category

Investigational obesity and metabolic therapy.

Patient Access

Generally limited to clinical trial participation.

Approval Snapshot

Retatrutide FDA Approval Status

Field	Current Information
Drug Name	Retatrutide
FDA Status	Not FDA Approved
Prescription Availability	Not available as an FDA-approved prescription medication
Drug Type	Investigational incretin-based therapy
Primary Use Interest	Weight loss, obesity treatment, metabolic disease research

Important: Since Retatrutide is not FDA approved, consumers should be cautious of online sellers, compounded claims, or unregulated versions marketed outside legitimate medical channels.

Comparison

Compared to Approved Weight-Loss Drugs

Retatrutide is frequently compared to FDA-approved therapies such as Wegovy and Zepbound, but its regulatory position is very different.

Wegovy

FDA approved for chronic weight management.

Zepbound

FDA approved for chronic weight management.

Retatrutide

Still investigational and not FDA approved.